Literature DB >> 26020601

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.

Stephan R Vavricka1, Gerhard Rogler, Claudine Gantenbein, Muriel Spoerri, Mareike Prinz Vavricka, Alexander A Navarini, Lars E French, Ekaterina Safroneeva, Nicolas Fournier, Alex Straumann, Florian Froehlich, Michael Fried, Pierre Michetti, Frank Seibold, Peter L Lakatos, Laurent Peyrin-Biroulet, Alain M Schoepfer.   

Abstract

BACKGROUND: Data evaluating the chronological order of appearance of extraintestinal manifestations (EIMs) relative to the time of inflammatory bowel disease (IBD) diagnosis is currently lacking. We aimed to assess the type, frequency, and chronological order of appearance of EIMs in patients with IBD.
METHODS: Data from the Swiss Inflammatory Bowel Disease Cohort Study were analyzed.
RESULTS: The data on 1249 patients were analyzed (49.8% female, median age: 40 [interquartile range, 30-51 yr], 735 [58.8%] with Crohn's disease, 483 [38.7%] with ulcerative colitis, and 31 [2.5%] with indeterminate colitis). A total of 366 patients presented with EIMs (29.3%). Of those, 63.4% presented with 1, 26.5% with 2, 4.9% with 3, 2.5% with 4, and 2.7% with 5 EIMs during their lifetime. Patients presented with the following diseases as first EIMs: peripheral arthritis 70.0%, aphthous stomatitis 21.6%, axial arthropathy/ankylosing spondylitis 16.4%, uveitis 13.7%, erythema nodosum 12.6%, primary sclerosing cholangitis 6.6%, pyoderma gangrenosum 4.9%, and psoriasis 2.7%. In 25.8% of cases, patients presented with their first EIM before IBD was diagnosed (median time 5 mo before IBD diagnosis: range, 0-25 mo), and in 74.2% of cases, the first EIM manifested itself after IBD diagnosis (median: 92 mo; range, 29-183 mo).
CONCLUSIONS: In one quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis. Occurrence of EIMs should prompt physicians to look for potential underlying IBD.

Entities:  

Mesh:

Year:  2015        PMID: 26020601     DOI: 10.1097/MIB.0000000000000429

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  42 in total

1.  Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.

Authors:  Konstantinos Karmiris; Anastasios Avgerinos; Aikaterini Tavernaraki; Christos Zeglinas; Pantelis Karatzas; Theodoros Koukouratos; Konstantinos A Oikonomou; Athanasios Kostas; Evanthia Zampeli; Vasileios Papadopoulos; Angeliki Theodoropoulou; Nikos Viazis; Dimitrios Polymeros; Spyridon Michopoulos; Giorgos Bamias; Andreas Kapsoritakis; Dimitrios G Karamanolis; Gerassimos J Mantzaris; Charalampos Tzathas; Ioannis E Koutroubakis
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

Review 2.  Role of MiRNAs in Inflammatory Bowel Disease.

Authors:  Bo Cao; Xin Zhou; Jiaojiao Ma; Wei Zhou; Wanli Yang; Daiming Fan; Liu Hong
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

3.  The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.

Authors:  Tianrun Cai; Tzu-Chieh Lin; Allison Bond; Jie Huang; Gwendolyn Kane-Wanger; Andrew Cagan; Shawn N Murphy; Ashwin N Ananthakrishnan; Katherine P Liao
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 4.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 5.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

Review 6.  Skin Manifestations of Inflammatory Bowel Disease.

Authors:  Thomas Greuter; Alexander Navarini; Stephan R Vavricka
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

7.  Assessment of Occult Pulmonary Involvement in Ulcerative Colitis.

Authors:  Sudhir J Gupta; Vineet L Gupta; Harit G Kothari; Amol R Samarth; Nitin R Gaikwad; Sahil M Parmar
Journal:  Inflamm Intest Dis       Date:  2020-07-01

8.  Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.

Authors:  Alicia Algaba; Iván Guerra; Elena Ricart; Eva Iglesias; Miriam Mañosa; Javier P Gisbert; Jordi Guardiola; Miguel Mínguez; Beatriz Castro; Ruth de Francisco; Pilar Nos; Federico Bertoletti; Francisco Mesonero; Jesús Barrio; María Dolores Martín-Arranz; Xavier Calvet; Santiago García-López; Beatriz Sicilia; Gillermo Alcaín; María Esteve; Lucía Márquez; Marta Piqueras; Laura Jiménez; José L Perez-Calle; Luis Bujanda; Mariana García-Sepulcre; Alejandra Fernández; Irene Moraleja; Rufo Humberto Lorente; Orlando García-Bosch; Ana Lambán; Isabel Blázquez; Esther Rodríguez; José M Huguet; Alfredo J Lucendo; Pedro Almela; David Busquets; Patricia Ramírez de la Piscina; Marcela Pérez; Eugeni Domenech; Fernando Bermejo
Journal:  Dig Dis Sci       Date:  2020-07-15       Impact factor: 3.199

9.  Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.

Authors:  David T Rubin; Walter Reinisch; Thomas Greuter; Paulo G Kotze; Marcia Pinheiro; Rajiv Mundayat; Eric Maller; Marc Fellmann; Nervin Lawendy; Irene Modesto; Stephan R Vavricka; Gary R Lichtenstein
Journal:  Therap Adv Gastroenterol       Date:  2021-05-16       Impact factor: 4.409

Review 10.  Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

Authors:  Gerhard Rogler; Abha Singh; Arthur Kavanaugh; David T Rubin
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.